These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31735756)

  • 21. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Wang LW; Li JL; Yu Y; Xiao RH; Huang HW; Kuang RR; Hai B
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):531-535. PubMed ID: 28786061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia.
    Takao T; Tsujimura A; Kiuchi H; Takezawa K; Okuda H; Yamamoto K; Fukuhara S; Miyagawa Y; Nonomura N
    Urology; 2013 Jul; 82(1):189-93. PubMed ID: 23642937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
    Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
    BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist].
    Tsujimura A; Takao T; Uchida K; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Hirai T; Kiuchi H; Miyagawa Y; Takahashi T; Kojimaan Y; Okuyama A
    Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):686-92. PubMed ID: 19999133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging drugs for the treatment of benign prostatic hyperplasia.
    Thomas D; Chughtai B; Kini M; Te A
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):201-212. PubMed ID: 28829208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives.
    Albisinni S; Biaou I; Marcelis Q; Aoun F; De Nunzio C; Roumeguère T
    BMC Urol; 2016 Sep; 16(1):58. PubMed ID: 27629059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Hakimi Z; Herdman M; Pavesi M; Devlin N; Nazir J; Hoyle C; Odeyemi IA
    Qual Life Res; 2017 May; 26(5):1187-1195. PubMed ID: 27896711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.
    Chapple CR; Roehrborn CG
    Eur Urol; 2006 Apr; 49(4):651-8. PubMed ID: 16530611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment.
    Jiang YH; Wang CC; Kuo HC
    PLoS One; 2018; 13(2):e0190704. PubMed ID: 29462145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
    Xu Z; Jia RP
    Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.